DeepMed Research

Chong Kun Dang Pharmaceutical Corp.

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: Public

Established: 1941-01-01

Employees: 2.3K

Market Cap: -

Website: http://www.ckdpharm.com

Clinical Trials

A Clinical Study to Evaluate the Efficacy and Safety of CKD-351

Phase 3

Conditions: Primary Open-angle Glaucoma
Ocular Hypertension

Interventions: Drug: Latanoprost
Drug: CKD-351
Drug: D930
Drug: Placebo of CKD-351
Drug: Placebo of D930

First Posted Date: 2018-12-03

Last Posted Date: 2018-12-03

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 384

Registration Number: NCT03762369

Locations: 🇰🇷
Seoul National University Hosipital, Seoul, Jongno, Korea, Republic of

Study to Evaluate the Efficacy and Safety of Once-Daily Tacrolimus in Kidney Transplant Recipients

Phase 4

Completed

Conditions: Kidney Transplant

Interventions: Drug: TacroBell SR cap.

First Posted Date: 2018-11-21

Last Posted Date: 2021-01-05

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 141

Registration Number: NCT03749356

Locations: 🇰🇷
Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of

Clinical Trial to Evaluate Pharmacokinetic Profiles and Safety Between CKD-385 and D935 in Healthy Volunteers

Phase 1

Conditions: Hypertension

Interventions: Drug: D935 Cap. 1T
Drug: CKD-385 Tab. 1T

First Posted Date: 2018-11-20

Last Posted Date: 2018-12-31

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 52

Registration Number: NCT03748212

Locations: 🇰🇷
Chonbuk National University Hospital, Jeonju, Korea, Republic of

The Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of CKD-387 Under Fed Condition

Phase 1

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: CKD-387
Drug: D484

First Posted Date: 2018-11-13

Last Posted Date: 2019-02-21

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 23

Registration Number: NCT03738449

Locations: 🇰🇷
Severance Hospital, Seoul, Korea, Republic of

Efficacy and Safety of CKD-501 Added to D150 Plus D745 10mg Therapy in Patients With Type 2 Diabetes

Phase 3

Completed

Conditions: Type2 Diabetes

Interventions: Drug: Placebo
Drug: CKD-501 0.5mg

First Posted Date: 2018-11-13

Last Posted Date: 2021-08-25

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 226

Registration Number: NCT03739125

Locations: 🇰🇷
Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of

A Study to Investigate Drug-Drug Interaction Between D326, D337 and CKD-828 in Healthy Subjects

Phase 1

Conditions: Dyslipidemias
Hypertension

Interventions: Drug: Sequence 1
Drug: Sequence 2
Drug: Sequence 3
Drug: Sequence 4
Drug: Sequence 5
Drug: Sequence 6

First Posted Date: 2018-11-01

Last Posted Date: 2018-11-01

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 30

Registration Number: NCT03726866

Locations: 🇰🇷
Asan Medical Center, University of Ulsan, Seoul, Korea, Republic of

The Clinical Trial to Evaluate the Efficacy and Safety of CKD-497

Phase 2

Completed

Conditions: Respiratory Infection

Interventions: Drug: CKD-497 200mg
Drug: CKD-497 300mg
Drug: CKD-497 placebo
Drug: Comparator placebo
Drug: Comparator

First Posted Date: 2018-11-01

Last Posted Date: 2020-02-06

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 220

Registration Number: NCT03726853

Locations: 🇰🇷
Korea University Anam hospital, Seoul, Seongbuk-gu, Korea, Republic of
🇰🇷
Kangbuk Samsung Hospital, Seoul, Jongno-gu, Korea, Republic of
🇰🇷
Hallym University Sacred Heart Hospital, Anyang, Gyeonggi-do, Korea, Republic of

and more 12 locations

CKD-504 in SAD and MAD in Healthy Korean and Caucasian Adult Male and Female Subjects

Phase 1

Conditions: Huntington Disease

Interventions: Drug: Placebo
Drug: CKD-504

First Posted Date: 2018-10-22

Last Posted Date: 2020-02-24

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 88

Registration Number: NCT03713892

Locations: 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of

Clinical Study to Compare the Pharmacokinetic Characteristics and Safety Between CKD-357 and D578 in Healthy Volunteers

Phase 1

Completed

Conditions: Acute Coronary Syndrome

Interventions: Drug: D578
Drug: CKD-357

First Posted Date: 2018-09-14

Last Posted Date: 2018-09-19

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 31

Registration Number: NCT03671941

Locations: 🇰🇷
Chonbuk National University Hospital, Jeonju, Korea, Republic of

Pharmacokinetics and Safety Profile of CKD-333

Phase 1

Completed

Conditions: Hypertension
Dyslipidemias

Interventions: Drug: CKD-333 formulation I
Drug: CKD-333 formulation II
Drug: CKD-330+D086

First Posted Date: 2018-09-06

Last Posted Date: 2018-10-31

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 37

Registration Number: NCT03659149

Locations: 🇰🇷
Seoul Saint Mary's Hospital, Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy